Brief: Sanuwave Health announces data from dermapace study for treatment of diabetic foot ulcers

SANUWAVE Health

24/03/2016 13:06

March 24 (Reuters) - Sanuwave Health Inc  SNWV.PK  
    * At 12 week endpoint total of 39 out of 172 of dermapace 
patients had complete wound closure, versus to 30 out of 164  in 
control group 
    * Announces 24-week data from its pivotal trials 
investigating use of dermapace for treatment of diabetic foot 
ulcers 
    * Primary safety endpoint throughout 24 week study was not 
statistically different between dermapace and sham-contro 
    * No statistically significant difference in wound closure 
at 12 week follow up between dermapace and control group 
 
Source text for Eikon:  ID:nGNXMQFFVa  
Further company coverage:  SNWV.PK  
 
 (Bengaluru Newsroom: +1-646-223-8780)